Literature DB >> 18317595

IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers.

Bin Zhang1, Theodore Karrison, Donald A Rowley, Hans Schreiber.   

Abstract

Tumors elicit antitumor immune responses, but over time they evolve and can escape immune control through various mechanisms, including the loss of the antigen to which the response is directed. The escape of antigen-loss variants (ALVs) is a major obstacle to T cell-based immunotherapy for cancer. However, cancers can be cured if both the number of CTLs and the expression of antigen are high enough to allow targeting of not only tumor cells, but also the tumor stroma. Here, we showed that IFN-gamma and TNF produced by CTLs were crucial for the elimination of established mouse tumors, including ALVs. In addition, both BM- and non-BM-derived stromal cells were required to express TNF receptors and IFN-gamma receptors for the elimination of ALVs. Although IFN-gamma and TNF were not required by CTLs for perforin-mediated killing of antigen-expressing tumor cells, the strong inference is that tumor antigen-specific CTLs must secrete IFN-gamma and TNF for destruction of tumor stroma. Therefore, bystander killing of ALVs may result from IFN-gamma and TNF acting on tumor stroma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18317595      PMCID: PMC2262029          DOI: 10.1172/JCI33522

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  61 in total

1.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.

Authors:  C Yee; J A Thompson; D Byrd; S R Riddell; P Roche; E Celis; P D Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-11       Impact factor: 11.205

Review 2.  Mechanisms of neutrophil-mediated killing of endothelial cells.

Authors:  P A Ward; J Varani
Journal:  J Leukoc Biol       Date:  1990-07       Impact factor: 4.962

3.  A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth.

Authors:  Andreas G Niethammer; Rong Xiang; Jürgen C Becker; Harald Wodrich; Ursula Pertl; Gabriele Karsten; Brian P Eliceiri; Ralph A Reisfeld
Journal:  Nat Med       Date:  2002-11-04       Impact factor: 53.440

4.  Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells.

Authors:  Michael T Spiotto; Ping Yu; Donald A Rowley; Michael I Nishimura; Stephen C Meredith; Thomas F Gajewski; Yang Xin Fu; Hans Schreiber
Journal:  Immunity       Date:  2002-12       Impact factor: 31.745

5.  Cutting edge: CD8+ effector T cells reject tumors by direct antigen recognition but indirect action on host cells.

Authors:  Thomas Schüler; Thomas Blankenstein
Journal:  J Immunol       Date:  2003-05-01       Impact factor: 5.422

6.  Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors.

Authors:  Thomas M J Niederman; Zoher Ghogawala; Bob S Carter; Hillary S Tompkins; Margaret M Russell; Richard C Mulligan
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-07       Impact factor: 11.205

7.  Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction.

Authors:  A F Ochsenbein; S Sierro; B Odermatt; M Pericin; U Karrer; J Hermans; S Hemmi; H Hengartner; R M Zinkernagel
Journal:  Nature       Date:  2001-06-28       Impact factor: 49.962

8.  VEGF-Trap: a VEGF blocker with potent antitumor effects.

Authors:  Jocelyn Holash; Sam Davis; Nick Papadopoulos; Susan D Croll; Lillian Ho; Michelle Russell; Patricia Boland; Ray Leidich; Donna Hylton; Elena Burova; Ella Ioffe; Tammy Huang; Czeslaw Radziejewski; Kevin Bailey; James P Fandl; Tom Daly; Stanley J Wiegand; George D Yancopoulos; John S Rudge
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205

9.  TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells.

Authors:  Christian H Poehlein; Hong-Ming Hu; Jane Yamada; Ilka Assmann; W Gregory Alvord; Walter J Urba; Bernard A Fox
Journal:  J Immunol       Date:  2003-02-15       Impact factor: 5.422

10.  Tumor regression by targeted gene delivery to the neovasculature.

Authors:  John D Hood; Mark Bednarski; Ricardo Frausto; Samira Guccione; Ralph A Reisfeld; Rong Xiang; David A Cheresh
Journal:  Science       Date:  2002-06-28       Impact factor: 47.728

View more
  79 in total

1.  Early tumor dissemination, but late metastasis: insights into tumor dormancy.

Authors:  Martin Röcken
Journal:  J Clin Invest       Date:  2010-05-24       Impact factor: 14.808

2.  Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation.

Authors:  Justin Kline; Long Zhang; Lauren Battaglia; Kenneth S Cohen; Thomas F Gajewski
Journal:  J Immunol       Date:  2012-02-06       Impact factor: 5.422

3.  Immunomodulatory IL-18 binding protein is produced by prostate cancer cells and its levels in urine and serum correlate with tumor status.

Authors:  Kazutoshi Fujita; Charles M Ewing; William B Isaacs; Christian P Pavlovich
Journal:  Int J Cancer       Date:  2010-11-16       Impact factor: 7.396

4.  Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice.

Authors:  Dhanalakshmi Chinnasamy; Zhiya Yu; Marc R Theoret; Yangbing Zhao; Rajeev K Shrimali; Richard A Morgan; Steven A Feldman; Nicholas P Restifo; Steven A Rosenberg
Journal:  J Clin Invest       Date:  2010-10-11       Impact factor: 14.808

5.  PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation.

Authors:  Megan Morisada; Paul E Clavijo; Ellen Moore; Lillian Sun; Michael Chamberlin; Carter Van Waes; James W Hodge; James B Mitchell; Jay Friedman; Clint T Allen
Journal:  Oncoimmunology       Date:  2017-11-27       Impact factor: 8.110

6.  CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.

Authors:  Julia Bluhm; Elisa Kieback; Stephen F Marino; Felix Oden; Jörg Westermann; Markus Chmielewski; Hinrich Abken; Wolfgang Uckert; Uta E Höpken; Armin Rehm
Journal:  Mol Ther       Date:  2018-06-18       Impact factor: 11.454

Review 7.  Tumor necrosis factor and cancer, buddies or foes?

Authors:  Xia Wang; Yong Lin
Journal:  Acta Pharmacol Sin       Date:  2008-11       Impact factor: 6.150

Review 8.  Intravital imaging of CD8+ T cell function in cancer.

Authors:  Thorsten R Mempel; Christian A Bauer
Journal:  Clin Exp Metastasis       Date:  2008-07-30       Impact factor: 5.150

9.  Engineering higher affinity T cell receptors using a T cell display system.

Authors:  Adam S Chervin; David H Aggen; John M Raseman; David M Kranz
Journal:  J Immunol Methods       Date:  2008-10-12       Impact factor: 2.303

10.  WEE1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy.

Authors:  Lillian Sun; Ellen Moore; Rose Berman; Paul E Clavijo; Anthony Saleh; Zhong Chen; Carter Van Waes; John Davies; Jay Friedman; Clint T Allen
Journal:  Oncoimmunology       Date:  2018-07-23       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.